Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Amendment No.: 4*
Name of Issuer: Collegium Pharmaceutical, Inc.
Title of Class of Securities: Common Stock
CUSIP Number: 19459J104
Date of Event Which Requires Filing of this Statement: 12/31/2021
Check the appropriate box to designate the rule pursuant to which
this Schedule is filed.
[X] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in
a prior cover page.
The information required in the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or otherwise subject to the
liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).
CUSIP No.: 19459J104
1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Janus Henderson Group plc
EIN #00-0000000
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
a. ___
b. ___
3. SEC USE ONLY
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Jersey, Channel Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
5. SOLE VOTING POWER
0**
6. SHARED VOTING POWER
3,774,303**
7. SOLE DISPOSITIVE POWER
0**
8. SHARED DISPOSITIVE POWER
3,774,303**
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,774,303**
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES
Not applicable
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
10.9%**
12. TYPE OF REPORTING PERSON
IA, HC
** See Item 4 of this filing
CUSIP No.: 19459J104
1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Janus Henderson Contrarian Fund
84-1521705
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
a. ___
b. ___
3. SEC USE ONLY
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Massachusetts
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
5. SOLE VOTING POWER
0**
6. SHARED VOTING POWER
1,300,294**
7. SOLE DISPOSITIVE POWER
0**
8. SHARED DISPOSITIVE POWER
1,300,294**
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,300,294**
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES
Not applicable
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
3.8%**
12. TYPE OF REPORTING PERSON
IV
** See Item 4 of this filing
Item 1.
(a). Name of Issuer: Collegium Pharmaceutical, Inc. ("Collegium")
(b). Address of Issuer's Principal Executive Offices:
100 Technology Center Drive
Stoughton, MA 02072
Item 2.
(a).-(c). Name, Principal Business Address, and Citizenship of
Persons
Filing:
(1) Janus Henderson Group plc
201 Bishopsgate
EC2M 3AE, United Kingdom
Citizenship: Jersey, Channel Islands
(2) Janus Henderson Contrarian Fund
151 Detroit Street
Denver, Colorado 80206
Citizenship: Massachusetts
(d). Title of Class of Securities: Common Stock
(e). CUSIP Number: 19459J104
Item 3.
This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) and the
person filing, Janus Henderson Group plc ("Janus Henderson"), is a
parent holding company/control person in accordance with Section
240.13d-1(b)(ii)(G). See Item 4 for additional information.
Janus Henderson Contrarian Fund is an Investment Company registered
under Section 8 of the Investment Company Act of 1940.
Item 4. Ownership
The information in items 1 and 5 through 11 on the cover page(s) on
Schedule 13G is hereby incorporated by reference.
Janus Henderson has an indirect 97% ownership stake in Intech
Investment Management LLC ("Intech") and a 100% ownership stake in
Janus Henderson Investors U.S. LLC ("JHIUS"), Henderson Global
Investors Limited ("HGIL") and Janus Henderson Investors Australia
Institutional Funds Management Limited ("JHIAIFML"), (each an "Asset
Manager" and collectively as the "Asset Managers"). Due to the above
ownership structure, holdings for the Asset Managers are aggregated
for purposes of this filing. Each Asset Manager is an investment
adviser registered or authorized in its relevant jurisdiction and
each furnishing investment advice to various fund, individual and/or
institutional clients (collectively referred to herein as "Managed
Portfolios").
As a result of its role as investment adviser or sub-adviser to the
Managed Portfolios, JHIUS may be deemed to be the beneficial owner of
3,768,148 shares or 10.9% of the shares outstanding of Collegium
Common Stock held by such Managed Portfolios. However, JHIUS does not
have the right to receive any dividends from, or the proceeds from
the sale of, the securities held in the Managed Portfolios and
disclaims any ownership associated with such rights.
Janus Henderson Contrarian Fund is an investment company registered
under the Investment Company Act of 1940 and is one of the Managed
Portfolios to which JHIUS provides investment advice.
Item 5. Ownership of Five Percent or Less of a Class
This statement is being filed to report the fact that Janus Henderson
Contrarian Fund has ceased to be the beneficial owner of more than
five percent of the class of securities.
Item 6. Ownership of More than Five Percent on Behalf of Another Person
The Managed Portfolios, set forth in Item 4 above, have the right to
receive all dividends from, and the proceeds from the sale of, the
securities held in their respective accounts.
The interest of any one Managed Portfolio does not exceed 5% of the
class of securities.
These shares were acquired in the ordinary course of business, and
not with the purpose of changing or influencing control of the Issuer.
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on by the Parent Holding Company
Intech, JHIUS, HGIL and JHIAIFML are indirect subsidiaries of Janus
Henderson and are registered investment advisers furnishing
investment advice to Managed Portfolios.
Item 8. Identification and Classification of Members of the Group
Not applicable.
Item 9. Notice of Dissolution of Group
Not applicable.
Item 10. Certification
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired in the
ordinary course of business and were not acquired for the purpose of
and do not have the effect of changing or influencing the control of
the issuer of such securities and were not acquired in connection
with or as a participant in any transaction having such purposes or
effect.
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true,
complete and correct.
JANUS HENDERSON GROUP PLC
By /s/ Kristin Mariani
Kristin Mariani, Head of North America Compliance, CCO
Date 2/10/2022
JANUS HENDERSON CONTRARIAN FUND
By /s/ Kristin Mariani
Kristin Mariani, Head of North America Compliance, CCO
Date 2/10/2022
Name/Title Attorney-In-Fact
The original statement shall be signed by each person on whose behalf
the statement is filed or his or her authorized representative. If
the statement is signed on behalf of a person by his or her
authorized representative other than an executive officer or general
partner of the filing person, evidence of the representative's
authority to sign on behalf of such person shall be filed with the
statement (see Exhibit A), provided, however, that a power of
attorney for this purpose which is already on file with the
Commission may be incorporated by reference. The name and any title
of each person who signs the statement shall be typed or printed
beneath his or her signature.
EXHIBIT A
POWER OF ATTORNEY
The undersigned, Janus Henderson Group plc ("the Company"), does
hereby make, constitute and appoint each of Kristin Mariani and
Caroline Barotti acting severally, as its true and lawful
attorneys-in-fact, for the purpose of, from time to time, executing
in its name and on its behalf, whether the Company individually or as
representative of others, any and all documents, certificates,
instruments, statements, other filings and amendments to the
foregoing (collectively, "documents") determined by such person to be
necessary or appropriate to comply with ownership or control-person
reporting requirements imposed by any United States or non-United
States governmental or regulatory authority, including, without
limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of
the foregoing as may be required to be filed with the Securities and
Exchange Commission, and delivering, furnishing or filing any such
documents with the appropriate governmental, regulatory authority or
other person, and giving and granting to each such attorney-in-fact
power and authority to act in the premises as fully and to all
intents and purposes as the Company might or could do if personally
present by one of its authorized signatories, hereby ratifying and
confirming all that said attorney-in-fact shall lawfully do or cause
to be done by virtue hereof. Any such determination by an
attorney-in-fact named herein shall be conclusively evidenced by such
person's execution, delivery, furnishing or filing of the applicable
document.
This power of attorney shall be valid from the date hereof and
shall remain in full force and effect until either revoked in
writing by the Company, or, in respect of any attorney-in-fact named
herein, until such person ceases to be an employee of the Company or
one of its affiliates.
IN WITNESS WHEREOF, the undersigned has caused this power of attorney
to be executed as of this 30th day of September, 2021.
Janus Henderson Group plc
By: /s/ Bruce Koepfgen
Name: Bruce Koepfgen
Title: Executive Vice President, Head of North America
EXHIBIT B
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of
1934, the persons named below agree to the joint filing on behalf of
each of them of a Statement on Schedule 13G (including amendments
thereto) with respect to the Common Stock of Collegium
Pharmaceutical, Inc. and further agree that this Joint Filing
Agreement be included as an Exhibit to such joint filings. In
evidence thereof, the undersigned hereby execute this Agreement as of
the 10th day of February, 2022.
JANUS HENDERSON GROUP PLC
By /s/ Kristin Mariani
Kristin Mariani, Head of North America Compliance, CCO
JANUS HENDERSON CONTRARIAN FUND
By /s/ Kristin Mariani
Kristin Mariani, Head of North America Compliance, CCO